NuGenerex Immuno-Oncology, Inc. will look for merger or acquisition opportunities. As of December 14, 2020, cash position is not sufficient for twelve months of operations. Generex has financed activities to date. Cash balances have remained low throughout fiscal 2021. Management may seek to meet all or some of operating cash flow requirements through financing activities, such as public or private placement of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. In addition, management is actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities, and potential strategic partners.